We showed that the expression levels of MMP-3 was inhibited by tocilizumab and etanercept treatment in RA patients, and the expression levels at initiation of biologic treatment did not affect clinical outcomes between tocilizumab and etanercept treatment. This evidence concerns the gene MMP3 and rheumatoid arthritis.